Zhejiang Xinguang Pharmaceutical Co., Ltd. (SHE:300519)
China · Delayed Price · Currency is CNY 14.10
-0.31 (-2.15%)
Sep 10, 2026, 3:04 PM CST
SHE:300519 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 62.02 | 54.21 | 50.39 | 64.36 | 108.82 | 114.28 |
Depreciation & Amortization | 14.02 | 14.74 | 14.93 | 14.77 | 14.05 | 12.86 |
Loss (Gain) From Sale of Assets | - | 0 | 0.07 | 0.29 | - | 0.71 |
Asset Writedown & Restructuring Costs | -0.39 | 0.04 | 0.01 | -0.02 | -0 | 0.49 |
Loss (Gain) From Sale of Investments | -6.98 | -5.63 | -4.87 | -4.07 | -4.32 | -6.42 |
Provision & Write-off of Bad Debts | -0.2 | -0.2 | 0.11 | -0.71 | 0.43 | - |
Other Operating Activities | 0.51 | 0.44 | 0.39 | 0.5 | 0.2 | - |
Change in Accounts Receivable | 0.26 | 4.93 | -2.69 | 14.4 | -8.44 | 2.93 |
Change in Inventory | 32.56 | 25.63 | 1.69 | -25.78 | 0.42 | -4.46 |
Change in Accounts Payable | -12.14 | -25.44 | -6.55 | -10.6 | 15.37 | 22.02 |
Operating Cash Flow | 89.88 | 68.92 | 53.43 | 53.29 | 126.43 | 142.36 |
Operating Cash Flow Growth | 42.36% | 28.99% | 0.27% | -57.85% | -11.19% | 26.41% |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Capital Expenditures | -0.45 | -3.48 | -5.2 | -15.99 | -16.64 | -14.71 |
Sale of Property, Plant & Equipment | 0 | 0.03 | 0.1 | 0.32 | 0.03 | 0.2 |
Investment in Securities | -208.12 | -215 | -30 | -40 | 10 | -36.8 |
Other Investing Activities | 192.39 | 5.94 | 5.14 | 4.29 | 4.55 | 6.78 |
Investing Cash Flow | -16.17 | -212.5 | -29.96 | -51.37 | -2.07 | -44.54 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Dividends Paid | -48 | -48 | -64 | -80 | -96 | -96 |
Financing Cash Flow | -48 | -48 | -64 | -80 | -96 | -96 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Cash Flow | 25.7 | -191.58 | -40.53 | -78.08 | 28.36 | 1.82 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 89.43 | 65.45 | 48.23 | 37.3 | 109.78 | 127.64 |
Free Cash Flow Growth | 51.75% | 35.69% | 29.30% | -66.02% | -13.99% | 24.72% |
Free Cash Flow Margin | 33.49% | 24.66% | 18.02% | 13.80% | 31.23% | 39.78% |
Free Cash Flow Per Share | 0.56 | 0.41 | 0.30 | 0.23 | 0.69 | 0.79 |
Levered Free Cash Flow | 74.84 | 45.19 | 23.2 | 7.05 | 71.83 | 87.81 |
Unlevered Free Cash Flow | 74.84 | 45.19 | 23.2 | 7.05 | 71.83 | 87.81 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash Income Tax Paid | 36.45 | 33.59 | 23.4 | 44.9 | 36 | 44.76 |
Change in Working Capital | 20.91 | 5.33 | -7.59 | -21.83 | 7.24 | 20.43 |